eligibility_summary
Inclusion: Consent, 14–75, ECOG 0–2, >3 mo survival, R/R CD19/20/22+ B‑ALL/lymphoma or BCMA+ MM, measurable disease, prior Tx: lymphoma anti‑CD20 + anthracycline, MM ≥3 lines incl PI+IMiD, adequate organ function. Exclusion: recent major CV/pulmonary disease, uncontrolled infection (incl active HBV/HCV, HIV/syphilis), autoimmune/immunodeficiency, severe allergy, <6 mo post‑allo‑HSCT or GvHD, recent VTE/anticoag, CNS disorders, pregnancy/lactation, recent prohibited drugs or DLI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial tests autologous CAR-T cell therapy (biologic, adoptive cellular gene therapy). Patient T cells are genetically engineered to express chimeric antigen receptors targeting B-lineage antigens CD19, CD20, and/or CD22 for B-ALL/B-cell lymphomas, and BCMA (TNFRSF17) for multiple myeloma. Mechanism: antigen binding independent of HLA triggers CAR intracellular CD3ζ/co-stimulatory signaling, activating T cells to proliferate, secrete cytokines, and kill tumor cells via perforin/granzyme, leading to depletion of malignant B cells/plasma cells (and on-target B-cell aplasia for CD19/20/22). Cells/pathways targeted: CD19/CD20/CD22-positive B-cell tumors (CLL, FL, MZL, LPL, HCL, DLBCL, BL, MCL) and BCMA-positive plasma cells, impacting B-cell receptor lineage and BCMA survival signaling. Phase 1, single-arm study in relapsed/refractory disease.